Enrollment is continuing for our long-term follow up study for our MDMA-assisted therapy parent studies. The long-term follow up study is open to individuals who participated and received MDMA in at least …
MAPS Europe is delighted to announce that on March 23, 2022, the first site in the United Kingdom was activated and will begin screening patients in our open-label Phase 2 study of MDMA-assisted therapy …
On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder …
Our Expanded Access Program study site at Sage Integrative Health in Berkeley, California, began screening participants for MDMA-assisted therapy for PTSD in early March. Our multi-site expanded access …
On March 17, 2022, MAPS submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the partial clinical hold issues in the MAPS-sponsored Study MPG1. The response upheld that …
MAPS Europe is delighted to announce that as of March 7, 2022, recruitment of patients into the MP18 study began at the Department of Psychiatry and Neurosciences in the Charité – Universitätsmedizin …
On February 28, 2022, the thirteenth study site in our multi-site open-label extension study of MDMA-assisted therapy for PTSD (MAPPUSX) officially began screening potential study participants. This study …
On February 28, 2022, the U.S. Food and Drug Administration (FDA) placed Study MPG1 on partial clinical hold, preventing the study from being initiated. FDA highlighted their concerns in the Partial Clinical …
Our multi-site expanded access study site for MDMA-assisted therapy for patients with treatment-resistant PTSD at the Pearl Psychedelic Institute in Waynesville, North Carolina, was activated for phone …
On February 3, 2022, the first participant was treated in the MAPS-sponsored Phase 2, open-label study of the comparative effectiveness of two vs. three MDMA-assisted therapy sessions in Veterans with …
On February 3, our Phase 3 study site for MDMA-assisted psychotherapy for PTSD in Tel Hashomer, Israel, officially opened for phone screenings and informed consent visits. Led by Principal Investigator …
In January 2022, our Phase 2 study to assess MDMA-assisted group therapy for the treatment of PTSD in veterans received full approval by the Institutional Review Board (IRB). The study is located at the …
